The control room of Euronext, the company that manages the Paris Stock Exchange (AFP / ERIC PIERMONT)
The Paris Stock Exchange is groping on Thursday, cautiously assessing the impact of Donald Trump's first announcements since his return to the White House.
Around 10:00 a.m., the CAC 40 lost 0.07% to 7,831.43 points, down 6.54 points. The day before, the flagship index had gained 0.86%, to 7,837.40 points.
“We must keep in mind that the Paris stock market is not immune to (…) the Trump risk,” summarized Christopher Dembik, investment strategy advisor at Pictet AM.
Back at the White House since Tuesday, the new American president has threatened a drastic increase in customs duties for Mexico and Canada from February, but also for the European Union and China.
If the absence of immediate measure initially reassured the European markets, which have climbed in recent days, a wait-and-see attitude is now in order.
Donald Trump's intervention by videoconference in Davos will in this context be particularly followed at 5 p.m.
The sequence is scheduled to last 45 minutes, with a question-and-answer session with big bosses whose list is still being finalized.
Meanwhile, earnings season is in full swing.
The French perfume giant Interparfums (+0.84% in Paris) presented its annual results on Thursday before the session, with increasing sales. The tourism specialist Pierre et Vacances will follow.
-In terms of indicators, the business climate remained stable at a low level in January in France, standing at 95 compared to 94 in December, a slight increase of one point.
In industry, the indicator which summarizes the business climate is down to 95 points, and business leaders are more pessimistic about order books.
Across the Atlantic, investors are awaiting US unemployment figures for the second week of January, published around 1:30 p.m. GMT. This index, decisive for evaluating the continuation of the monetary policy of the Federal Reserve (Fed), is highly scrutinized.
On the bond side, the interest rate on the French ten-year loan reached 3.27%, compared to 3.26% the day before at closing. Its German equivalent, a benchmark in Europe, reached 2.53%.
Success for Valneva
The Franco-Austrian pharmaceutical group Valneva published “positive results” in children on Wednesday evening for its phase 2 clinical trial evaluating the effects of its single-injection vaccine candidate against the chikungunya virus. “The results of this study (…) could make it possible to launch a phase 3 study in children” from “the fourth quarter of 2025”, according to the group.
The company's stock climbed 1.76% to 2.20 euros on the SBF 120.
Euronext CAC40
